TORONTO, Aug. 8 /CNW/ - Bradmer Pharmaceuticals Inc., a biopharmaceutical
company dedicated to the development and commercialization of cancer
therapies, today announced senior management appointments, effective
immediately. Dr. Alan M. Ezrin, Ph.D., has been promoted to Chief Executive
Officer from his previous position as Chief Operating Officer. Brian Brohman,
Chief Financial Officer, has taken on the additional role of Chief Business
"Dr. Ezrin's more than 25 years of experience in research and business
development in both the pharmaceutical and biotechnology sectors has enhanced
Bradmer's management capabilities since he joined our team a year ago," said
Dr. Mark C. Rogers, Executive Chairman. "Alan's promotion was a natural step
for Bradmer as we increase our clinical focus with the initiation of our
multicenter Phase III trial for Neuradiab targeted for later this year. Alan's
experience, leadership and extensive knowledge of the biopharmaceutical
industry combined with his expertise in executing sophisticated clinical
trials on schedule and within budget will be invaluable to Bradmer."
"Mr. Brohman's promotion to Chief Business Officer recognizes his
additional responsibilities with respect to licensing and business development
opportunities," said Dr. Alan Ezrin, Chief Executive Officer of Bradmer. "As
we enter a pivotal stage in our development, Brian's wealth of knowledge and
ability to identify growth prospects is a perfect complement to the dynamic
management team we have established."
Dr. Mark C. Rogers, previously Chief Executive Officer will now hold the
title Executive Chairman.
About Bradmer Pharmaceuticals Inc. (www.bradmerpharma.com)
Bradmer Pharmaceuticals is a biopharmaceutical company focused on the
development and commercialization of new and innovative cancer therapies.
Bradmer's lead clinical candidate, Neuradiab, was developed at Duke University
Medical Center as a proprietary therapy for a particularly aggressive form of
brain cancer, glioblastoma multiforme. To date, over US$60 million in grants
and related support has driven research and development of the licensed
treatment, which has been delivered to over 200 patients with promising
results and has completed Phase II clinical trials at Duke University. Bradmer
is currently in the process of organizing a pivotal multi-center clinical
trial of the licensed treatment. Neuradiab has been granted Orphan Drug Status
by both the U.S. Food and Drug Administration and the European Medicines
Bradmer Pharmaceuticals Inc.'s common shares have not been registered
under the Securities Act of 1933, as amended (the "Securities Act") or any
state regulatory agency in the United States. The resale or transfer by a U.S.
investor of such common shares of Bradmer Pharmaceuticals Inc. is subject to
the requirements of Rule 904 of Regulation S of the Securities Act or such
other applicable exemption thereunder, and other applicable state securities
Except for historical information, this press release may contain
forward-looking statements, which reflect the Company's current expectation
regarding future events. These forward-looking statements involve risk and
uncertainties, which may cause but are not limited to, changing market
conditions, the successful and timely completion of clinical studies, the
establishment of corporate alliances, the impact of competitive products and
pricing, new product development, uncertainties related to the regulatory
approval process and other risks detailed from time to time in the Company's
ongoing quarterly and annual reporting.
For further information:
For further information: Bradmer Pharmaceuticals Inc., Mr. Brian
Brohman, Chief Business and Financial Officer, Phone: (416) 361-6058 (Ext.
804), E-mail: firstname.lastname@example.org, Internet: www.bradmerpharma.com;
Investor Relations, Ross Marshall, The Equicom Group Inc., Phone: (416)
815-0700 (Ext. 238), Fax: (416) 815-0080, E-mail: email@example.com